INTEGRAL A BIOTECHNOLOGY COMPANY ENTERS THE DENTAL MARKET

LAUNCHES FIRST PRODUCT TO DIAGNOSE PERI-IMPLANT DISEASE

WASHINGTON D.C. Oct./30/2024 – Today Integral Dental announces the launch of its first product, OraclePI, the only early diagnostic test for peri-implant disease. The test delivers a disease diagnosis and personalized care plan recommendations based on patient specific data. Dental implants represent an important option for patients with missing teeth. While implant success rates are high, the greatest risk of failure is an infection of the surrounding tissue, called peri-implantitis. Integral’s new product, OraclePI enables clinicians to gain insight into 100% of the bacteria present at the implant site, diagnoses the state of infection, and makes recommendations on most effective antibiotics and other treatments. “This has the potential to improve patient outcomes and drive profitability for dental practices,” said Rachel Raymond, CEO of Integral Dental. “As the demand for implants grows, we’re excited to offer an option for personalized management.”

By combining cutting-edge genomic sequencing and AI, OraclePI empowers dentists with actionable insights to improve patient outcomes through personalized care. “We’ve worked hard to make sure our processes fit seamlessly into the daily workflow of the dental office,” said Matt Getz, COO of Integral Dental, “our $110/test cost to dentists is part of the innovation we’re bringing to the table.” Earlier interventions in peri-implant disease are often more effective and less invasive than if they are performed at more advanced stages of infection. Performing a diagnostic test as part of routine implant management can help clinicians identify problems early and keep their patients healthy. “The specific antibiotic recommendations give us the opportunity to practice true personalized medicine,” said Dr. Peter Joseph, DMD, Clinical Advisor to Integral Dental, “I plan to integrate this tool into my practice and ask all my referring doctors to do the same. The better the information, the better we can help patients.”

Diagnosing peri-implant disease is just the beginning for Integral’s technology platform. Integral’s vision extends beyond oral health to addressing systemic diseases triggered by oral pathogens, such as cardiovascular disease, pre-term birth, rheumatoid arthritis, and colon cancer. When we diagnose and treat oral pathogens early and effectively, healthcare costs reduce precipitously, and patient outcomes improve. Integral Dental continues to explore innovative applications for OraclePI, building bridges between oral health and broader medical care.
Call to Action: OraclePI is now available for purchase and is being offered in 10 kit packs for a limited time. To learn more and add Integral to the services offering your patients, visit IntegralDental.bio.

About Integral

Integral is a biotechnology company dedicated to closing the gap between oral and systemic health. The innovation is based on

Next Generation Sequencing and Machine Learning technology and driven by co-founders Rachel Raymond and Matt Getz. The founders bring extensive biotech and healthcare executive experience, MBAs from Harvard Business School, and a passion for preventative medicine to this large, global health problem. Integral is a resident company of Johnson & Johnson Innovation - JLABS, a premier life science incubator program in Washington, DC.